IP Library › Granted Patent US 12,529,023
Granted Patent B2
US 12,529,023 · App. 17/078,157 · Granted Jan 20, 2026

Cell expansion vessel systems and methods

Inventors: Weston Blaine Griffin (Niskayuna, NY); Xiaohua Zhang (Niskayuna, NY); Reginald Donovan Smith (Schnectady, NY); Vandana Keskar (Schnectady, NY)
Assignee: Global Life Sciences Solutions USA LLC
C12M29/04C12M23/08C12M23/24C12M25/02C12M25/06C12M29/18C12M29/26C12M33/00C12M41/46C12N5/0636
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,529,023
App. No.
17/078,157
Granted
Jan 20, 2026
Kind
B2
Abstract

A method includes introducing a suspension including cells suspended in a cell culture medium through a feed port or a drain port into a cavity of a cell culture vessel, the suspension being in an amount sufficient to cover a gas permeable, liquid impermeable membrane positioned at a bottom of the cell culture vessel, the feed port being disposed through a surface of the cell culture vessel and configured to permit additional cell culture medium into the cavity, and the drain port being disposed through the surface of the cell culture vessel and configured to permit removal of the cells, cell culture medium, and used cell culture medium from the cavity, allowing the cells to settle on the gas permeable, liquid impermeable membrane by gravity, removing the used cell culture medium through the drain port and introducing the additional cell culture medium through the feed port such that a constant volume is maintained in the cell culture vessel until the cells expand to a desired cell density, wherein the removing and introducing are performed subsequent to allowing the cells to settle on the gas permeable, liquid impermeable membrane, resuspending the cells in the cell culture medium in the cell culture vessel, wherein the resuspending is performed after the desired cell density is attained, and removing the resuspended cells and the cell culture medium through the drain port.

Claims (27)

1 . A cell culture vessel for expansion of a cell density, comprising:

a bottom plate comprising a grid surface configured to provide support and gas exchange;

a vessel body coupled to the bottom plate, wherein the vessel body comprises a rigid concave structure;

a cavity formed by the vessel body and the bottom plate;

a gas-permeable, liquid impermeable membrane disposed above the bottom plate within the cavity;

a feeding port disposed through a surface of the vessel body, wherein the feeding port is configured to permit addition of cell culture medium into the cavity; and

a drain port disposed through a wall of the vessel body, wherein the drain port is configured to permit removal of used cell culture medium from the cavity;

wherein the cell culture vessel is configured to hold a suspension comprising cells suspended in the cell culture medium, and wherein the cell culture medium within the cell culture vessel comprises a ratio of cell culture medium volume per surface area of the gas permeable, liquid impermeable membrane that is below a predetermined threshold value; and

wherein the drain port is disposed below a surface of the cell culture medium within the cavity and at or above the gas permeable, liquid impermeable membrane when the cavity contains the cell culture medium and the cells, and wherein the drain port is further configured to permit cell removal from the cavity of the cell culture vessel.

2 . The cell culture vessel of claim 1 , wherein the cell culture vessel comprises an angled side, wherein the angled side comprises the side wall of the vessel body and a corresponding side of the bottom plate, wherein the angled side comprises a point, and wherein the drain port is disposed at the point of the angled side.

3 . The cell culture vessel of claim 1 , wherein the threshold value comprises a ratio of cell culture medium volume per surface area of the gas permeable, liquid impermeable membrane between 0.3 and 2.

4 . The cell culture vessel of claim 1 , wherein the drain port is further configured to permit removal of cells from the cavity.

5 . The cell culture vessel of claim 1 , wherein a constant volume is maintained in the cell culture vessel until the cells expand to a desired cell density.

6 . The cell culture vessel of claim 1 , wherein cell culture medium is introduced through the feeding port and removed through the drain port simultaneously.

7 . The cell culture vessel of claim 1 , wherein the cell culture vessel enables cell expansion via perfusion.

8 . The cell culture vessel of claim 7 , wherein the perfusion is continuous.

9 . The cell culture vessel of claim 1 , wherein a volume equal to the volume of the cell culture vessel is exchanged over one day.

10 . The cell culture vessel of claim 1 , wherein the cell culture vessel may be tilted toward the drain port for harvest of cell culture.

11 . The cell culture vessel of claim 1 , wherein the vessel body is transparent.

12 . The cell culture vessel of claim 1 , wherein the bottom plate is formed of a non-solid structure.

13 . The cell culture vessel of claim 1 , wherein the membrane is a cell culture surface.

14 . The cell culture vessel of claim 1 , wherein the membrane has a thickness of less than 0.01 inches.

15 . The cell culture vessel of claim 1 , wherein the membrane comprises silicon.

16 . The cell culture vessel of claim 1 , further comprising a mesh sheet disposed between the bottom plate and the membrane.

17 . The cell culture vessel of claim 16 , wherein the mesh sheet comprises polyester mesh.

18 . The cell culture vessel of claim 1 , further comprising an O-ring to seal the cell culture vessel when the vessel body is coupled to the bottom plate.

19 . The cell culture vessel of claim 1 , further comprising an air filter.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2020
From: GENERAL ELECTRIC COMPANY
To: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
Reel/Frame 054203/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2020
From: GRIFFIN, WESTON BLAINE; ZHANG, XIAOHUA; SMITH, REGINALD DONOVAN; KESKAR, VANDANA
To: GENERAL ELECTRIC COMPANY
Reel/Frame 054146/0127 →
Continuity (2)
Division 15893336 · Feb 9, 2018
Related Publication 20210054328A1 · Feb 25, 2021
References Cited (228)
US 4033825A · Haddad et al. · 1977 [cited by applicant]
US 4143764A · Moss · 1979 [cited by applicant]
US 4291786A · Ito · 1981 [cited by applicant]
US 4601730A · McGowan et al. · 1986 [cited by applicant]
US 5117870A · Goodale et al. · 1992 [cited by applicant]
US 5449617A · Falkenberg · 1995 [cited by examiner]
US 5506117A · Andrews et al. · 1996 [cited by applicant]
US 5686304A · Codner et al. · 1997 [cited by applicant]
US 5693537A · Wilson et al. · 1997 [cited by applicant]
US 5707869A · Wolf et al. · 1998 [cited by applicant]
US 5726450A · Peterson et al. · 1998 [cited by applicant]
US 5985153A · Dolan et al. · 1999 [cited by applicant]
US 6410309B1 · Barbera-Guillem et al. · 2002 [cited by applicant]
US 6455310B1 · Barbera-Guillem · 2002 [cited by applicant]
US 6479252B1 · Barbera-Guillem et al. · 2002 [cited by applicant]
US 6821772B2 · Barbera-Guillem et al. · 2004 [cited by applicant]
US 6900055B1 · Fuller et al. · 2005 [cited by applicant]
US 7601545B2 · Barringer, Jr. · 2009 [cited by applicant]
US 7745209B2 · Martin · 2010 [cited by examiner]
US 7919307B2 · Klaus et al. · 2011 [cited by applicant]
US 7964392B2 · Hatano et al. · 2011 [cited by applicant]
US 8158427B2 · Wilson · 2012 [cited by examiner]
US 8492140B2 · Smith et al. · 2013 [cited by applicant]
US 8956860B2 · Vera et al. · 2015 [cited by applicant]
US 9110114B2 · Nezuka et al. · 2015 [cited by applicant]
US 9175253B2 · Hata · 2015 [cited by applicant]
US 9206383B2 · Vunkak-Novakovic · 2015 [cited by applicant]
US 9255243B2 · Wilson et al. · 2016 [cited by applicant]
US 9315774B2 · Knaus et al. · 2016 [cited by applicant]
US 9441192B2 · Wilson et al. · 2016 [cited by applicant]
US 9732317B2 · Wilson et al. · 2017 [cited by applicant]
US 10350245B2 · Adair et al. · 2019 [cited by applicant]
US 10458920B2 · Planas et al. · 2019 [cited by applicant]
US 10889792B2 · Griffin et al. · 2021 [cited by applicant]
US 11236298B2 · Stone et al. · 2022 [cited by applicant]
US 11414639B2 · Griffin et al. · 2022 [cited by applicant]
US 11920119B2 · Griffin et al. · 2024 [cited by applicant]
US 11932842B2 · Griffin et al. · 2024 [cited by applicant]
US 20020055166A1 · Cannon et al. · 2002 [cited by applicant]
US 20020146816A1 · Vellinger et al. · 2002 [cited by applicant]
US 20020189374A1 · Desilets et al. · 2002 [cited by applicant]
US 20040214314A1 · Srienc et al. · 2004 [cited by applicant]
US 20050051723A1 · Neagle et al. · 2005 [cited by applicant]
US 20050180891A1 · Webster et al. · 2005 [cited by applicant]
US 20050230767A1 · Park et al. · 2005 [cited by applicant]
US 20080000902A1 · Holbrook et al. · 2008 [cited by applicant]
US 20080227190A1 · Antwiler · 2008 [cited by applicant]
US 20090037031A1 · George et al. · 2009 [cited by applicant]
US 20090286315A1 · Pattou et al. · 2009 [cited by applicant]
US 20100236340A1 · Lee · 2010 [cited by applicant]
US 20100291534A1 · Higuchi et al. · 2010 [cited by applicant]
US 20110020179A1 · Yue et al. · 2011 [cited by applicant]
US 20110136225A1 · Vunjak-Novakovic et al. · 2011 [cited by applicant]
US 20120149021A1 · Yung et al. · 2012 [cited by applicant]
US 20130109081A1 · Tsuchiya · 2013 [cited by applicant]
US 20130157353A1 · Dijkhuizen Borgart · 2013 [cited by examiner]
US 20130206597A1 · Wang et al. · 2013 [cited by applicant]
US 20140335608A1 · Tanaka · 2014 [cited by applicant]
US 20150072401A1 · Nozaki et al. · 2015 [cited by applicant]
US 20150090664A1 · Nokleby et al. · 2015 [cited by applicant]
US 20150329815A1 · Wilson · 2015 [cited by applicant]
US 20150344833A1 · Kimura et al. · 2015 [cited by applicant]
US 20160215257A1 · Davis et al. · 2016 [cited by applicant]
US 20160319233A1 · Shimase et al. · 2016 [cited by applicant]
US 20160340633A1 · Davis · 2016 [cited by applicant]
US 20160355777A1 · Fachin et al. · 2016 [cited by applicant]
US 20170058242A1 · Martin et al. · 2017 [cited by applicant]
US 20170253847A1 · Koseki · 2017 [cited by applicant]
US 20180066248A1 · Kusner et al. · 2018 [cited by applicant]
US 20180272347A1 · Zenhausern et al. · 2018 [cited by applicant]
US 20180298321A1 · Koseki et al. · 2018 [cited by applicant]
US 20200392446A1 · Griffin et al. · 2020 [cited by applicant]
US 20210087510A1 · Griffin et al. · 2021 [cited by applicant]
US 20210102157A1 · Griffin et al. · 2021 [cited by applicant]
CN 1501835A · 2004 [cited by applicant]
CN 101014712A · 2007 [cited by applicant]
CN 102504991A · 2012 [cited by applicant]
CN 104640973A · 2015 [cited by applicant]
CN 105392877A · 2016 [cited by applicant]
CN 106459915A · 2017 [cited by applicant]
CN 106466495A · 2017 [cited by applicant]
CN 106536055A · 2017 [cited by applicant]
CN 106573241A · 2017 [cited by applicant]
CN 107454862A · 2017 [cited by applicant]
EP 0950432A1 · 1999 [cited by applicant]
EP 1944359A1 · 2008 [cited by applicant]
EP 2589652A1 · 2013 [cited by applicant]
EP 3081627A1 · 2016 [cited by applicant]
EP 3196289A1 · 2017 [cited by applicant]
GB 2268187A · 1994 [cited by applicant]
JP S55177534U · 1980 [cited by applicant]
JP S57100900A · 1982 [cited by applicant]
JP 2002542004A · 2002 [cited by applicant]
JP 2003504195A · 2003 [cited by applicant]
JP 2006149232A · 2006 [cited by applicant]
JP 2007535965A · 2007 [cited by applicant]
JP 2009502183A · 2009 [cited by applicant]
JP 2009514796A · 2009 [cited by applicant]
JP 2013223820A · 2013 [cited by applicant]
JP 2013539356A · 2013 [cited by applicant]
JP 2014033889A · 2014 [cited by applicant]
JP 2015188391A · 2015 [cited by applicant]
JP 2015221002A · 2015 [cited by applicant]
JP 2015223169A · 2015 [cited by applicant]
JP 2016221001A · 2015 [cited by applicant]
JP 2016153124A · 2016 [cited by applicant]
JP 2016170623A · 2016 [cited by applicant]
JP 2017513499A · 2017 [cited by applicant]
JP 2021512633A · 2021 [cited by applicant]
KR 1020080072006A · 2008 [cited by applicant]
KR 1020160145162A · 2016 [cited by applicant]
WO 199600780A1 · 1996 [cited by applicant]
WO 9724144A1 · 1997 [cited by applicant]
WO 0950432A1 · 1999 [cited by applicant]
WO 2000050175A1 · 2000 [cited by applicant]
WO 02070120A1 · 2002 [cited by applicant]
WO 02102965A2 · 2002 [cited by applicant]
WO 03087292A2 · 2003 [cited by applicant]
WO 2005009126A1 · 2005 [cited by applicant]
WO 2005108589A1 · 2005 [cited by applicant]
WO 2007052718A1 · 2007 [cited by applicant]
WO 2008109200A1 · 2008 [cited by applicant]
WO 2009072003A2 · 2009 [cited by applicant]
WO 2009112952A2 · 2009 [cited by applicant]
WO 2010040748A1 · 2010 [cited by applicant]
WO 2010062599A1 · 2010 [cited by applicant]
WO 2010080032A2 · 2010 [cited by applicant]
WO 2012079000A1 · 2012 [cited by applicant]
WO 2013114845A1 · 2013 [cited by applicant]
WO 2013184800A2 · 2013 [cited by applicant]
WO 2014051503A1 · 2014 [cited by applicant]
WO 2015001321A1 · 2015 [cited by applicant]
WO 2015042450A1 · 2015 [cited by applicant]
WO 2015039115A1 · 2015 [cited by applicant]
WO 2015056302A1 · 2015 [cited by applicant]
WO 2015120096A2 · 2015 [cited by applicant]
WO 2015162211A1 · 2015 [cited by applicant]
WO 2016007216A1 · 2016 [cited by applicant]
WO 2016012459A2 · 2016 [cited by applicant]
WO 2016100227A1 · 2016 [cited by applicant]
WO 2016107788A1 · 2016 [cited by applicant]
WO 2016113369A1 · 2016 [cited by applicant]
WO 2016118780A1 · 2016 [cited by applicant]
WO 2016161174A1 · 2016 [cited by applicant]
WO 2016168687A1 · 2016 [cited by applicant]
WO 2016185221A1 · 2016 [cited by applicant]
WO 2016189159A1 · 2016 [cited by applicant]
WO 2017032829A1 · 2017 [cited by applicant]
WO 2017035262A1 · 2017 [cited by applicant]
WO 2017038887A1 · 2017 [cited by applicant]
WO 201760534A1 · 2017 [cited by applicant]
WO 201785899A1 · 2017 [cited by applicant]
WO 2017109083A1 · 2017 [cited by applicant]
WO 2017109074A1 · 2017 [cited by applicant]
WO 2017144440A2 · 2017 [cited by applicant]
WO 2017190254A1 · 2017 [cited by applicant]
WO 2017221155A1 · 2017 [cited by applicant]
WO 2018005521A2 · 2018 [cited by applicant]
WO 2018111931A1 · 2018 [cited by applicant]
WO 2018122192A1 · 2018 [cited by applicant]
WO 2019046766A2 · 2019 [cited by applicant]
WO 2019155026A1 · 2019 [cited by applicant]
WO 2019155030A1 · 2019 [cited by applicant]
WO 2019155031A2 · 2019 [cited by applicant]
Office Action and Search Report Issued in Chinese Patent Application No. 202080010621.1, dated Sep. 5, 2022 with English Translation (21 pages). [cited by applicant]
Office Action Issued in Japanese Patent Application No. 2020-529614, dated Sep. 12, 2022 with English Summary (12 pages). [cited by applicant]
Japanese Office Action for JP Application No. 2020-542856, mailed Jan. 10, 2023 (8 pages, with English translation). [cited by applicant]
Japanese Office Action for JP Application No. 2020-542889, mailed Jan. 10, 2023 (22 pages, with English translation). [cited by applicant]
Japanese Office Action for JP Application No. 2020-542847, mailed Jan. 10, 2023 (10 pages, with English translation). [cited by applicant]
Japanese Office Action for JP Application No. 2020-542846, mailed Dec. 23, 2022 (9 pages, with English translation). [cited by applicant]
Japanese Office Action for JP Application No. 2020-542890, mailed Jan. 4, 2023 (9 pages, with English translation). [cited by applicant]
Indian First Examination Report for IN Application No. 202017032170 mailed Jul. 8, 2022 (5 pages). [cited by applicant]
Singapore Written Opinion for SG Application No. 11202004646T mailed Aug. 6, 2021 (6 pages). [cited by applicant]
Singapore Written Opinion for SG Application No. 11202007140X mailed Aug. 2, 2021 (7 pages). [cited by applicant]
Singapore Written Opinion for SG Application No. 11202007439T mailed Aug. 2, 2021 (6 pages). [cited by applicant]
Chinese Office Action for CN Application No. 202080010621.1 mailed Sep. 5, 2022 (21 pages, with English translation). [cited by applicant]
Japanese Office Action for JP Application No. 2020-529614 mailed Sep. 12, 2022 (12 pages, with English translation). [cited by applicant]
Schwarz, Ray P., et al.; “Cell Culture For Three-Dimensional Modeling in Rotating-Wall Vessels: An Application of Simulated Microgravity”, Journal of tissue culture methods, vol. 14, Issue 02, pp. 51-57, Jun. 1992. [cited by applicant]
Hung, Paul J., et al.; “A Novel High Aspect Ratio Microfluidic Design to Provide a Stable and Uniform Microenvironment for cell Growth in a High Throughput Mammalian Cell Culture Array”, Link of General Homepage, vol. 0… [cited by applicant]
Shojaosadati, Seyed Abbas, et al.; “Recent Advances in High Cell Density Cultivation for Production of Recombinant Protein”, Iranian Journal of Biotechnology, vol. 06, Issue 02, pp. 63-84, 2008. [cited by applicant]
International Search Report for PCT/EP Application No. 2019/053210, issued May 22, 2019 (13 pages). [cited by applicant]
International Search Report for PCT/EP Application No. 2019/053209, issued May 13, 2019 (14 pages). [cited by applicant]
International Search Report for PCT/EP Application No. 2019/053212, issued May 27, 2019 (9 pages). [cited by applicant]
International Search Report for PCT/EP Application No. 2019/053208, issued May 21, 2019 (13 pages). [cited by applicant]
International Search Report for PCT/EP Application No. 2019/053206, issued May 15, 2019 (12 pages). [cited by applicant]
Rnational Search Report for PCT/EP Application No. 2019/053211, issued May 29, 2019 (10 pages). [cited by applicant]
International Search Report for PCT/EP Application No. 2019/053205, issued Apr. 30, 2019 (12 pages). [cited by applicant]
International Search Report for PCT/EP Application No. 2019/053207, issued May 3, 2019 (13 pages). [cited by applicant]
U.S. Office Action issued Mar. 21, 2022 in corresponding U.S. Appl. No. 16/968,342; 32 pages. [cited by applicant]
Japanese Office Action for JP Application No. 2020-542891, mailed Jan. 26, 2023 (8 pages, with English translation). [cited by applicant]
United States Office Action for U.S. Appl. No. 16/968,342, mailed Apr. 6, 2023 (26 pages). [cited by applicant]
Korean Office Action for KR Application No. 10-2020-7025562 mailed Sep. 19, 2023 (20 pages, with English translation). [cited by applicant]
Korean Office Action for KR Application No. 10-2020-7025576 mailed Sep. 19, 2023 (19 pages, with English translation). [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,304, dated Oct. 5, 2023 (12 pages). [cited by applicant]
First Office Action issued in China application No. 201980024225.1, dated Sep. 1, 2023 (18 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,333, dated Sep. 20, 2023 (8 pages). [cited by applicant]
First Office Action issued in China application No. 201980024234.0, dated Aug. 29, 2023 (15 pages). [cited by applicant]
First Office Action issued in China application No. 201980024224.7, dated Aug. 31, 2023 (22 pages). [cited by applicant]
First Office Action issued in China application No. 201980024223.2, dated Aug. 16, 2023 (24 pages). [cited by applicant]
First Office Action issued in China application No. 201980024235.5, dated Aug. 30, 2023 (15 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,374, dated Jan. 17, 2024 (46 pages). [cited by applicant]
Hollyman et al. “Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.” Journal of Immunotherapy, vol. 32(2): pp. 169-180. (Year: 2009). [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,315, dated Jan. 17, 2024, 28 pages. [cited by applicant]
Office Action issued in China Application No. 201880088322.2, dated Dec. 21, 2023, 7 pages. [cited by applicant]
Examination Report issued in Australian Application No. 2019219295, dated Nov. 30, 2023, 3 pages. [cited by applicant]
Examination Report issued in Australian Application No. 2019219292, dated Dec. 7, 2023, 3 pages. [cited by applicant]
Examination Report issued in Indian Application No. 202017032170, dated Feb. 5, 2024, 2 pages. [cited by applicant]
Examination Report issued in Australian Application No. 2019219241, dated Nov. 28, 2023, 3 pages. [cited by applicant]
Office Action in Chinese Application No. 201980024013.3, dated May 1, 2024, 7 pages. [cited by applicant]
Office Action in Chinese Application No. 201980024222.8, dated May 29, 2024, 12 pages. [cited by applicant]
Office Action issued in United States U.S. Appl. No. 17/734,562, dated Feb. 26, 2024, 70 pages. [cited by applicant]
Office Action issued in United States U.S. Appl. No. 17/734,562, dated May 2, 2022, 15 pages. [cited by applicant]
Office Action issued in KR Application No. 10-2020-7018529, mailed Sep. 13, 2024, 12 pages. [cited by applicant]
Perfusion culture of T lymphocytes in the WAVE Bioreactor tm System 2/10 (software version 2.61), GE Healthcare Life Sciences, Cell Expansion, Application note 28-9650-52 AC, 9 pages. [cited by applicant]
Mock, et al. “Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy Using CliniMACS Prodigy”, Cytotherapy, 2016' 18: 1002-1011, 11 pages. [cited by applicant]
Office Action issued in MX Application No. MX/a/2020/008317, mailed Aug. 22, 2024, 12 pages. [cited by applicant]
Singh, “Disposable bioreactor for cell culture using wave-induced agitation”, Cytotechnology, 30 :: 149-158, 1999. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,304, mailed Dec. 19, 2024, 28 pages. [cited by applicant]
Office Action issued in CA Application No. 3082861, mailed Mar. 11, 2025, 6 pages. [cited by applicant]
Office Action issued in JP Application No. 2023-215870, mailed Feb. 18, 2025. [cited by applicant]
Office Action issued in CA Application No. 3,090,047, mailed Jun. 20, 2025, 4 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 18/400,052, mailed May 21, 2025, 70 pages. [cited by applicant]
Office Action issued in AU Application No. 2019219291, mailed Sep. 11, 2024, 3 pages. [cited by applicant]
Office Action issued in Japanese application No. 2023-215870, dated Aug. 25, 2025 (6 pages), English translation. [cited by applicant]
Office Action issued in Canadian application No. 3,090,447, dated Aug. 15, 2025 (6 pages). [cited by applicant]
Office Action issued in Canadian application No. 3,089,788, dated Aug. 15, 2025 (6 pages). [cited by applicant]
https://catalog.takara-bio.co.jp/PDFS/retronection_201601.pdf, “For Increasing Efficiency in Gene Transfer Using Retrovirus/Lentivirus? RetroNectin”, [online], 2021, Acquisition Date: Aug. 25, 2025 (3 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 17/423,202, dated Aug. 4, 2025, 23 pages. [cited by applicant]